TreatSMA

Cost of Living Grant

Yesterday Muscular Dystrophy UK launched a Cost of Living Grant for people living with muscle-wasting or weakening conditions.

Applications are open from 27th March to 6th  April. The grants will be a one-time payment in the form of a supermarket voucher, at a value of £150, and are limited to one per household.

For more information, please see this webpage: https://www.musculardystrophyuk.org/cost-of-living-grant.

Please use this link to apply for a cost of living grant: https://mduk.smartsimpleuk.com/s_signup.jsp?token=XVtQC1oGYFxaSxBRXxJXQVZUZUl3E3U%3D.

Please save a copy of your supporting letter (for example, a Clinical letter or a GP letter) as a PDF and upload it to the form (the option to do so will become available after you click ‘save’ on the form).
If you have any questions, please contact MDUK by email on costofliving@musculardystrophyuk.org.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more